fda glp-1 compounding and Novo Nordisk Warn of Telehealth Take Down – What's Next? GLP-1 Medications – FDA Guidance

2018, pp

A team of researchers developed a nanostructure-based GLP-1R agonist capable of crossing the BBB that significantly attenuated neuroinflammation and memory loss in an A peptide-induced mouse model of AD by inhibiting the inflammatory responses of microglia and astrocytes (Zhao et al., 2022)

Although there are currently no FDA-approved oral GLP-1 medications for weight loss, early data from clinical trials hint that a pill form could be as effective as its injectable counterparts

Furthermore, in the Asian phase III trial, exposure was similar among patients from the three countries (China, India and South Korea) [35]